Zacks Research Issues Pessimistic Outlook for JAZZ Earnings

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Analysts at Zacks Research cut their Q3 2026 earnings estimates for shares of Jazz Pharmaceuticals in a research report issued on Thursday, October 9th. Zacks Research analyst Team now anticipates that the specialty pharmaceutical company will post earnings per share of $4.72 for the quarter, down from their prior estimate of $4.73. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q1 2027 earnings at $4.20 EPS, Q3 2027 earnings at $5.44 EPS and FY2027 earnings at $20.52 EPS.

A number of other brokerages have also weighed in on JAZZ. The Goldman Sachs Group raised their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, October 8th. Finally, Truist Financial raised their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $178.93.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $135.14 on Monday. The company’s fifty day moving average price is $126.25 and its 200 day moving average price is $115.66. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $148.06. The stock has a market capitalization of $8.20 billion, a P/E ratio of -20.08, a P/E/G ratio of 8.32 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the prior year, the business posted $5.30 EPS. Jazz Pharmaceuticals’s revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Hurley Capital LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $25,000. Picton Mahoney Asset Management raised its holdings in Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after buying an additional 269 shares during the period. Spire Wealth Management raised its holdings in Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 161 shares during the period. SVB Wealth LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $36,000. Finally, Hantz Financial Services Inc. raised its holdings in Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 297 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director owned 429,973 shares in the company, valued at $55,303,127.26. The trade was a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.